Our Strategy

Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity. Our portfolio of investigational spleen tyrosine kinase (SYK) inhibitors are being developed to treat certain genetic subtypes of acute myeloid leukemia, one of the most difficult-to-treat blood cancers. We are also developing KB-0742, a selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) for the treatment of MYC-dependent solid tumors. In addition, we have multiple oncology discovery programs targeting dysregulated transcription factors.

Our Science

Targeting dysregulated transcription factors in cancer

Addressing the complexity of oncogenic TRNs requires a sophisticated and holistic approach to targeting cancer biology. TRNs encompass hundreds of proteins that function in a coordinated fashion to orchestrate specific gene expression programs that control development and function of healthy cells. Dysregulated TRNs resulting from aberrant transcription factor expression or activity are frequently responsible for reprogramming healthy cells into cancerous tumor cells. We apply computational biology to map the TRNs and identify the critical nodes and gene expression signatures that drive cancer. We believe that these critical nodes present attractive targets for therapeutic intervention using a biomarker-driven precision medicine strategy.

Product Engine

Our product engine includes four interconnected components, each of which is informed by our translational expertise, that enable efficient, hypothesis-driven clinical development of our product candidates:

map icon
screen icon
optimize icon
validate

Identify gene expression signature of selective TRN modulation

Conduct high throughput SMM screens in tumor cell lysates to identify selective TRN modulators

Refine pharmacological properties to yield attractive product development candidates

Hypothesis driven clinical trials to deliver proof of concept early in the development process

map icon

Identify gene expression signature of selective TRN modulation​

screen icon

Conduct high throughput SMM screens in tumor cell lysates to identify selective TRN modulators

optimize icon

Refine pharmacological properties to yield attractive development candidates

validate

Hypothesis driven clinical trials to deliver proof of concept early in the development process

Pipeline/Programs

We have developed a robust clinical and preclinical pipeline through a combination of internal discovery efforts and focused asset acquisition. The following chart summarizes our product pipeline, including our lead product candidate, ENTO, as well as our discovery programs and our next anticipated milestones.

TRN

Investigational Therapy

Discovery

IND-Enabling Studies

Phase 1 Trial

Phase 2 Trial

Phase 3 Trial

Next Anticipated Milestone

Mid 2021: Initiate Registrational Phase 3 clinical trial

Late 2021: Initiate Phase 1/2 clinical trial in combination with gilteritinib

Early 2022: Initiate Phase 1/2 clinical trial in combination with venetoclax/azacitidine

MYC

Q4 2021: Initial safety, PK and PD data from Phase 1/2 clinical trial dose escalation cohorts

MYB, AR, IRF4, ASCL1, MYC

First IND filing among these programs in 2022*

*We may not be successful in identifying product candidates that can selectively modulate the specific oncogenic TRNs associated with such programs.

Color Band

Careers

JOIN OUR TEAM

woman in lab
woman in lab
woman in lab

We are looking for innovative team members who share our passion for transformative science paired with unparalleled execution.

See our current list of openings below or submit your resume to careers@kronosbio.com.

we’re building the highway, not filling potholes”

‟we’re building the highway, not filling potholes”

marius pop
Marius Pop
Director, Biology